EP0295836A2 - Utilisation de dérivés de dioxopiperidine pour la fabrication d'une préparation topique comme analgesique - Google Patents

Utilisation de dérivés de dioxopiperidine pour la fabrication d'une préparation topique comme analgesique Download PDF

Info

Publication number
EP0295836A2
EP0295836A2 EP19880305317 EP88305317A EP0295836A2 EP 0295836 A2 EP0295836 A2 EP 0295836A2 EP 19880305317 EP19880305317 EP 19880305317 EP 88305317 A EP88305317 A EP 88305317A EP 0295836 A2 EP0295836 A2 EP 0295836A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydrogen
methyl
alkoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19880305317
Other languages
German (de)
English (en)
Other versions
EP0295836B1 (fr
EP0295836A3 (en
Inventor
Malcolm Henry Traffod Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878714033A external-priority patent/GB8714033D0/en
Priority claimed from GB878714374A external-priority patent/GB8714374D0/en
Application filed by BTG International Ltd, British Technology Group Ltd filed Critical BTG International Ltd
Priority to AT88305317T priority Critical patent/ATE80035T1/de
Publication of EP0295836A2 publication Critical patent/EP0295836A2/fr
Publication of EP0295836A3 publication Critical patent/EP0295836A3/en
Application granted granted Critical
Publication of EP0295836B1 publication Critical patent/EP0295836B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Definitions

  • This invention relates to the use of certain 3-phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines as analgesics.
  • the invention provides the use of the said dioxopiperidines in the manufacture of analgesic medicaments, topical compositions comprising said dioxopiperidines, and methods of analgesic treatment using said dioxopiperidines.
  • Morphine in various forms has been used to suppress pain perception (i.e. as an analgesic) for about 3,000 years. Even today, morphine and related opioids remain the most potent and frequently used of the analgesics . However, these drugs have serious adverse side effects which limit their use. To varying extents, they are addictive, severely affect gut motility, and depress respiration to a dangerous degree. Further, patients become adapted to them requiring ever increasing doses to obtain relief. The drugs are abused by those who become addicted to them and hence their availability is restricted.
  • An object of this invention is to provide a class of analgesic compounds of which at least some do not exhibit said adverse side effects.
  • GB 1455687 discloses that 3-phenyl-3-aminoalkyl-4- and/or 5-methyl-2,6-dioxopiperidine derivatives have central nervous system, especially antidepressant, activity.
  • Said compounds include, inter alia , those of the following Formula A.
  • R1 represents hydrogen or C1-C4 alkyl
  • R3 represents hydrogen or C1-C4 alkyl
  • R4 represents C1-C4 alkyl
  • R5 and R6 independently represent hydrogen or methyl
  • A represents C1-C6 alkylene
  • m is 0 to 3
  • Y is hydroxy, C1-C4 alkoxy, C1-C4 alkyl, C1-C4 hydroxyalkyl, halogen or trifluoromethyl.
  • At least one compound of Formula A (viz 3-(3′-methoxy-phenyl)-3-(3 ⁇ -N,N-dimethylaminopropyl) -4,4-dimethyl-2,6-dioxopiperidine; AGN 2979) also blocks in vitro the activation of tryptophan hydroxylase resulting from exposure of brain stem slices to metabolic inhibitors or methylxanthines or induced by incubation of supernatant preparations of the enzyme under phosphorylating conditions (Boadle-Biber, M.C. et al Biochem. Pharmacol. 35 , 1521-6, (1986)).
  • AGN 2979 has no significant effect in vitro upon the unactivated enzyme (Boadle-Biber, M.C. et al supra).
  • R1 represents hydrogen or C1-C4 alkyl
  • n is 1 or 2
  • R2 represents hydrogen or methyl, provided that one R2 is hydrogen when n is 2
  • R3 represents hydrogen or C1-C2 alkyl
  • R4 represents C1-C2 alkyl
  • R5 and R6 independently represent hydrogen or methyl
  • m is 0 to 3
  • each Y is in a meta or para position and independently represents hydroxy, C1-C2 alkoxy, C1-C2 alkyl, C1-C2 hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position, or a pharmacologically acceptable salt thereof.
  • the invention provides a method of providing an analgesic effect in a patient suffering pain, other than migraine headache, which comprises administering to the patient an analgesic effective amount of a compound of the following Formula I.
  • R1 represents hydrogen or C1-C4 alkyl
  • n is 1 or 2
  • R2 represents hydrogen or methyl, provided that one R2 is hydrogen when n is 2
  • R3 represents hydrogen or C1-C2 alkyl
  • R4 represents C1-C2 alkyl
  • R5 and R6 independently represent hydrogen or methyl
  • m is 0 to 3
  • each Y is in a meta or para position and independently represents hydroxy, C1-C2 alkoxy, C1-C2 alkyl, C1-C2 hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position, or a pharmacologically acceptable salt thereof.
  • a topical analgesic composition comprising, in a topical vehicle, a compound of the following Formula I: wherein: R1 represents hydrogen or C1-C4 alkyl; n is 1 or 2; R2 represents hydrogen or methyl, provided that one R2 is hydrogen when n is 2; R3 represents hydrogen or C1-C2 alkyl; R4 represents C1-C2 alkyl; R5 and R6 independently represent hydrogen or methyl; m is 0 to 3; and each Y is in a meta or para position and independently represents hydroxy, C1-C2 alkoxy, C1-C2 alkyl, C1-C2 hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position, or a pharmacologically acceptable salt thereof.
  • Formula I wherein: R1 represents hydrogen or C1-C4 alkyl; n is 1 or 2; R2 represents hydrogen or methyl, provided that one R2 is hydrogen when n is 2; R
  • the compounds of Formula I can be used to treat any condition requiring analgesic to suppress pain perception and in particular can be used as a substitute for opioid analgesics.
  • they can be used for human or veterinary treatment of any painful condition resulting from disease, injury, surgery or any form of trauma.
  • pain to be treated by the compounds of the invention include chronic pain, intractable pain, pain subject to spontaneous remission, post-operative pain, phantom limb pain, vascular headache, and the like pain.
  • treatment of pain associated with migraine headache is excluded from the invention having regard to the previous proposal to use certain of the compounds in the treatment of migraine. It is to be noted that said previous use was not to exploit the analgesic activity of the compounds, which activity was unknown until now.
  • the compounds of Formula I can be prepared in the manner disclosed in GB 1455687. They exist as optical isomers and can be used in racemate form or as individual (+) or (-) isomers. Presently, the (-) isomer is preferred.
  • the compounds of Formula I can be administered in various manners to achieve the desired analgesic effect.
  • the compounds can be administered enterally, parenterally, or topically, to the patient being treated.
  • Oral administration is likely to be the preferred route in most circumstances but injection intramuscularly, subcutaneously, intravenously or into other tissue will be preferred in some circumstances.
  • Intrathecal injection directly into the sub or supra arachnoid spaces of the spinal cord may be preferred for presurgical medication, postoperative trauma, childbirth and certain other conditions.
  • Topical application to the skin or the buccal or anal mucosa may be used for local or general pain, inflamation or irritation.
  • the amount of compound administered will vary and can be any analgesic effective amount. Depending upon the patient and the mode of administration, the quantity of compound administered may vary over a wide range to provide from about 0.01 mg/kg to 20 mg/kg, usually 0.1 mg/kg to 10 mg/kg of body weight of the patient per unit dose. Unit doses of these compounds can contain, for example, from about 1 mg to 500 mg, usually 10 to 100 mg, of the compound and may be administered, for example, from 1 to 4 times daily.
  • unit dosage form is used herein to mean a single or multiple dose form containing a quantity of the active ingredient in admixture with or otherwise in association with a diluent or carrier, said quantity being such that one or more predetermined units are normally required for a single therapeutic administration.
  • said predetermined unit will be one fraction, such as a 5 ml (teaspoon) quantity of a liquid or a half or quarter of a scored tablet, of the multiple dose form.
  • the compounds of general Formula I can have the phenyl moiety substituted in one or both meta positions by C1-C2 alkyl, C1-C2 hydroxyalkyl, halogen, trifluoromethyl, or, preferably, hydroxy or C1-C2 alkoxy. Additionally or alternatively, the phenyl moiety can be substituted in the para position by the aforementioned groups other than hydroxy and alkoxy. It is presently preferred that the substituent(s) should be hydroxy or, especially, methoxy. It is also preferred that one or both meta positions are substituted and that, when there are two substituents, they should be the same.
  • the amino group of the compounds of Formula I can be secondary or tertiary having methyl or ethyl groups attached to the nitrogen atom. Dimethylamino presently is preferred.
  • the piperidine ring of the compounds of Formula I is substituted in the 4-position with methyl and optionally by one or two further methyl groups in the 4 and/or 5 positions. It is presently preferred that there is one further methyl group in the 4 or 5 position, especially in the 4-position.
  • the ring nitrogen atom of the piperidine ring can be substituted with a C1-C4 alkyl group but it is presently preferred that said nitrogen atom is unsubstituted.
  • the C1-C2 alkyl groups or moieties referred to herein are methyl or ethyl; methyl presently being preferred.
  • the C3-C4 alkyl groups which may be substituents on the nitrogen atom of the piperidine ring can be straight or branched chain but the straight chain n-propyl or n-butyl groups presently are preferred.
  • the halogen substituent(s) in the phenyl ring can be chlorine, bromine or fluorine; chlorine presently being preferred.
  • n is 1 or 2; R2 represents hydrogen or methyl, provided that one R2 is hydrogen when n is 2; R3 represents hydrogen or C1-C2 alkyl; R4 represents C1-C2 alkyl; R5 and R6 independently represent hydrogen or methyl; and Y1 and Y2 independently represent hydrogen, hydroxy or C1-C2 alkoxy, or a pharmacologically acceptable salt thereof.
  • the presently especially preferred compounds of Formula 1A are those of the following Formula IB. wherein: n is 1 or 2; R3′ and R4 independently represent C1-C2 alkyl; R5 and R6 independently represent hydrogen or methyl; Y1′ represents hydroxy or C1-C2 alkoxy; and Y2′ represents hydrogen, hydroxy or C1-C2 alkoxy, or a pharmacologically acceptable salt thereof.
  • Examples of compounds of Formula IC include the following:- 3-(3′-methoxyphenyl)-3-(2 ⁇ -N,N-dimethylaminoethyl)-4,4-­dimethyl-2,6-dioxopiperidine 3-(3′-methoxyphenyl)-3-(3 ⁇ -N,N-dimethylaminopropyl)-­4,4-dimethyl-2,6-dioxopiperidine (compound 2979 - see later); 3-(3′-methoxyphenyl)-3-(2 ⁇ -N,N-diethylaminoethyl)-4,4-­dimethyl-2,6-dioxopiperidine; 3-(3′-methoxyphenyl)-3-(3 ⁇ -N,N-diethylaminopropyl)-­4,4-dimethyl-2,6-dioxopiperidine; 3-(3′-hydroxyphenyl)-3-(2 ⁇ -N,N
  • Examples of other compounds of Formula I include:- 3-phenyl-3-(2′-N,N-dimethylaminoethyl)-4-methyl-2,6-­dioxopiperidine; 3-phenyl-3-(2′-N,N-dimethylaminoethyl)-4,4-dimethyl-2,6­-dioxopiperidine; 3-phenyl-3-(2′-N,N-dimethylaminoethyl)-4,5-dimethyl-2,6­-dioxopiperidine; 3-phenyl-3(3′-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6­-dioxopiperidine; 3-(4′-chlorophenyl)-3(3 ⁇ -N,N-dimethylaminopropyl)-4,4-­dimethyl-2,6-dioxopiperidine; and 3-phenyl-3(2′ N-methylaminoethyl
  • the compounds of Formula I may be administered in free base form, as an alkali metal or alkaline earth metal salt or as a pharmaceutically acceptable acid addition salt with the proviso that an alkali metal or alkaline earth metal salt is not normally combined with an acid addition salt except in a layer formulation.
  • Representative acid addition salt forms include organic acid salt forms such as the maleate and methane sulphonate and mineral acid salt forms such as the hydrochloride and perchlorate.
  • the pharmaceutical formulations in which form the active compounds of the invention will normally be utilized are prepared in a manner well known per se in the pharmaceutical art and usually comprise at least one active compound of Formula I in admixture or otherwise in association with a pharmaceutically acceptable carrier or diluent therefor.
  • a pharmaceutically acceptable carrier or diluent for making those formulations the active ingredient will usually be mixed with a carrier, or diluted by a diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other container.
  • a carrier or diluent may be solid, semi-solid or liquid material which serves as a vehicle, excipient or medium for the active ingredient. Suitable carriers or diluents are well known per se .
  • the formulations may be adapted for enteral or parenteral use and may be administered to the patient in the form of tablets, capsules, dragees, suppositories, syrups, suspensions or the like.
  • the formulations may be adapted for topical application to the skin or mucosal surface and examples of such formulations are ointments, gels, creams, impregnated dressings, sprays or inhalants.
  • the formulations may be in delayed or sustained release form.
  • compositions may contain pharmaceutically inert organic or inorganic adjuvants, optionally granulating agents, binding agents lubricants, dispersing agents, wetting agents and preservatives.
  • pharmaceutical compositions may contain colouring, flavouring and sweetening substances.
  • Adjuvants for the production of tablets may be e.g. calcium carbonate, lactose micro-crystalline cellulose, mannitol or talc.
  • Starch and alginic acid or micro-crystalline cellulose may be used as granulating and disintegrating agents, starch, polyvinylpyrrolidone and gelatine may be used as binding agents and magnesium stearate, stearic acid, colloidal silica and talc as lubricants.
  • Tablet formulation may be coated or uncoated, the coating having the purpose of delaying the disintegration and absorption in the gastrointestinal tract.
  • Suitable suspending agents for the production of liquid administration forms are e.g. methyl cellulose and sodium alginate.
  • Capsule formulation may contain the active agents on their own or together with an inert solid diluent e.g. calcium phosphate, corn starch, lactose, or mannitol.
  • Tablets each having the following conposition are prepared by conventional techniques: mg/tablet (a) Compound AGN 2979 base 50 (b) Lactose 51.5 (c) Maize starch dried 45 (d) Magnesium stearate 1.5
  • the compound (a) is powdered and passed through a BS No. 100 sieve and triturated with molten oil of Theobroma at 45°C to form a smooth suspension.
  • the mixture is well stirred and poured into moulds each of nominal 1 G capacity to produce suppositories.
  • the mixture is compressed into 1000 tablets each weighing 138 mg.
  • the pills are prepared by blending the active ingredient (a) and the corn starch, then adding the liquid glucose with thorough kneading to form a plastic mass from which the pills are cut and formed.
  • a capsule is prepared by passing dry powdered active ingredient (a) and powdered talc in the above proportions through a fine mesh screen and mixing them well. The powder is then filled into hard gelatin capsules at a net fill of 72.5mg per capsule.
  • the stearyl alcohol and white petroleum jelly are melted at 75°C and mixed with an aqueous solution of the other ingredients preheated to 75°C. The mixture is stirred until it congeals and allowed to cool before packing into jars or other containers.
  • This Example illustrates the analgesic activity of compounds of Formula I.
  • Two groups of 5 male Wistar rats were studied. A first rat was placed into a 7 cm diameter glass tube for 1 minute and returned to the home cage for 9 minutes during which time a second rat was placed into the glass tube and the process was repeatedly cycled through 10 rats for more than 2 hours. During the period in the tube, the tail of the rat was laid over a wire coil at room temperature and a low voltage current was then passed through the wire coil sufficient to raise the temperature of the coil by 9.1°C. per second. After approximately 3 seconds, the temperature of the coil reached 42-45°C which can be subjectively determined by the experimenter to be a noxious temperature. At about this time the rat flicked the tail away from the coil and the precise latency of the tail-flick was recorded. This latency is a linear index of the temperature which the rat detected as noxious.
  • each rat received a coded subcutaneous injection.
  • One group received 2 mg/kg (-) AGN 2979 and one group received 2 mg/kg of morphine. The measurement of tail-flick latencies continued.
  • Tables 1 and 2 are recorded in Tables 1 and 2 below and the results are presented in Figure 1, which is a graph of average "Index of Analgesia" against time post-injection.
  • the Index of Analgesia was calculated according to the formula:- where control TFL is the average of the 3 tail-flick latencies of the rat taken before injection of the drug and T is the maximum number of seconds that the experimenter allowed the tail to remain in contact with the coil in the absence of a tail flick reflex (this is necessary to prevent damage to the tail of rats that are insensitive to painful stimuli).
  • the index of analgesia produces data that can be averaged ⁇ s.e. between animals within a group.
  • An index of 0 means no change from control latencies, and an index of 1 means maximum detectable insensitivity to noxious heat.
  • TABLE 1 (-) AGN 2979 TAIL-FLICK LATENCY (SECONDS) TIME* MINUTES SUBJECT NUMBER 1 2 3 4 5 0 3.6 3.5 3.1 3.4 3.4 10 3.1 3.4 3.2 3.1 3.4 20 3.3 3.3 3.3 3.0 3.5 30 5.3 4.4 6.0 5.0 40 4.9 6.0 6.0 6.0 50 6.0 6.0 5.7 6.0 60 5.9 4.9 6.0 5.9 4.9 70 5.9 5.2 5.3 4.7 5.5 80 4.7 4.6 4.9 4.9 4.8 90 4.6 4.4 4.7 4.2 4.7 100 4.1 4.5 4.9 3.9 4.2 110 4.1 3.7 4.0 3.5 3.5 120 3.7 3.4 3.6 3.2 3.3 * 2 mg/kg (-) AGN 2979 s.c.
  • Table 3 gives the tail-flick latency and Figure 2 shows the Index of Analgesia for the effect of naloxone on the analgesia caused by (-) AGN 2979. It can be seen that naloxone fails to reduce the potency of AGN 2979. This strongly suggests that AGN 2979 does not act on opioid receptors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP88305317A 1987-06-16 1988-06-10 Utilisation de dérivés de dioxopiperidine pour la fabrication d'une préparation topique comme analgesique Expired - Lifetime EP0295836B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT88305317T ATE80035T1 (de) 1987-06-16 1988-06-10 Verwendung von dioxopiperidin-derivaten zur herstellung eines topischen praeparates als analgetika.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878714033A GB8714033D0 (en) 1987-06-16 1987-06-16 Dioxopiperidine derivatives as analgesics
GB8714033 1987-06-16
GB8714374 1987-06-19
GB878714374A GB8714374D0 (en) 1987-06-19 1987-06-19 Dioxopiperidine derivatives

Publications (3)

Publication Number Publication Date
EP0295836A2 true EP0295836A2 (fr) 1988-12-21
EP0295836A3 EP0295836A3 (en) 1989-07-19
EP0295836B1 EP0295836B1 (fr) 1992-09-02

Family

ID=26292364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88305317A Expired - Lifetime EP0295836B1 (fr) 1987-06-16 1988-06-10 Utilisation de dérivés de dioxopiperidine pour la fabrication d'une préparation topique comme analgesique

Country Status (10)

Country Link
US (1) US4871750A (fr)
EP (1) EP0295836B1 (fr)
JP (1) JPS6416763A (fr)
AU (1) AU606424B2 (fr)
DE (1) DE3874229T2 (fr)
DK (1) DK328288A (fr)
GB (1) GB2205745B (fr)
IL (1) IL86745A0 (fr)
PH (1) PH24807A (fr)
PT (1) PT87737B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177086A (en) * 1988-11-10 1993-01-05 National Research Development Corporation Memory-enhancing compositions containing dioxopiperidine derivatives
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5866143A (en) * 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6011022A (en) * 1998-03-03 2000-01-04 El Khoury; George F. Topical application of muscarinic analgesic drugs such as neostigmine
US5994330A (en) * 1998-11-09 1999-11-30 El Khoury; Georges F. Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2212147A1 (fr) * 1972-12-28 1974-07-26 Aspro Nicholas Ltd
US4461771A (en) * 1983-03-01 1984-07-24 Gittos Maurice W Treatment of migraine with dioxopiperidine derivatives
GB2153821A (en) * 1984-01-25 1985-08-29 Glaxo Group Ltd 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives
EP0269303A2 (fr) * 1986-11-11 1988-06-01 Novo Nordisk A/S Dérivés du pipéridine pour le traitement de la douleur

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2181346B (en) * 1985-09-11 1989-10-04 Nat Res Dev Pharmaceutical compositions and medical uses of dioxopiperidine derivatives
CA1316112C (fr) * 1986-09-08 1993-04-13 Maurice Ward Gittos Compositions anxiolytiques contenant des derives dioxopiperidine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2212147A1 (fr) * 1972-12-28 1974-07-26 Aspro Nicholas Ltd
US4461771A (en) * 1983-03-01 1984-07-24 Gittos Maurice W Treatment of migraine with dioxopiperidine derivatives
GB2153821A (en) * 1984-01-25 1985-08-29 Glaxo Group Ltd 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives
EP0269303A2 (fr) * 1986-11-11 1988-06-01 Novo Nordisk A/S Dérivés du pipéridine pour le traitement de la douleur

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dorland s Medical Dictionary, p.825 *

Also Published As

Publication number Publication date
DE3874229T2 (de) 1993-03-25
AU1767688A (en) 1988-12-22
DK328288A (da) 1988-12-17
PH24807A (en) 1990-10-30
GB2205745B (en) 1990-09-19
IL86745A0 (en) 1988-11-30
US4871750A (en) 1989-10-03
GB8813796D0 (en) 1988-07-13
JPS6416763A (en) 1989-01-20
GB2205745A (en) 1988-12-21
PT87737B (pt) 1994-09-30
EP0295836B1 (fr) 1992-09-02
DK328288D0 (da) 1988-06-15
AU606424B2 (en) 1991-02-07
DE3874229D1 (de) 1992-10-08
EP0295836A3 (en) 1989-07-19
PT87737A (pt) 1989-05-31

Similar Documents

Publication Publication Date Title
US4753789A (en) Method for treating nausea and vomiting
EP0216555B1 (fr) Utilisation de dérivés de la dioxopipéridine pour le traitement de l'anxiété, pour la réduction des niveaux de la sérotonine ou de l'acide 5-hydroxy-indoleacétique chroniquement anormalement élevés dans le cerveau, et pour le traitement des infections bact
EP0185420A1 (fr) Compositions pharmaceutiques de dihydrocodéine/ibuprofène et méthode
EP0295836B1 (fr) Utilisation de dérivés de dioxopiperidine pour la fabrication d'une préparation topique comme analgesique
HU206042B (en) Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
KR101630467B1 (ko) 진통 내성 억제제
CA2284774C (fr) Compositions antitussives a base de theobromine
US5578632A (en) Medicaments for the treatment of gastrointestinal dysfunction
JPH11501282A (ja) コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体
US5057519A (en) 5-HT3 antagonists: use in reducing opiate tolerance
KR20070085470A (ko) 핫플러쉬 치료용 ｓ-미르타자핀
WO2002013807A2 (fr) Composes pour le traitement de troubles toxicomanogenes
US4877800A (en) Antipsychotic compositions containing dioxopiperidine derivatives
AU2001283393A1 (en) Compounds for the treatment of addictive disorders
CA1322523C (fr) Traitement des lesions du systeme nerveux central avec des antagonistes de recepteurs morphiniques
WO1998038997A1 (fr) Utilisation de la levobupivacaine en association avec des opioides ou des alfa2-agonistes comme anesthesiants ou analgesiques
US4721714A (en) Anti-vertigo drug
US20090170900A1 (en) Dosing regimen for weight loss
MXPA01013421A (es) Agentes terapeuticos.
WO2007016771A1 (fr) Regime de dosage pour perte de poids
EA015503B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
JP2003503452A (ja) 治療剤
WO1988009605A2 (fr) Traitement de lesions cerebrales traumatiques et ischemiques avec des antagonistes de recepteurs d'opiaces
GB2213058A (en) Opiate addiction composition containing buprenorphine and naltrexone
ZA200300220B (en) Compounds for the treatment of addictive disorders.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19890801

17Q First examination report despatched

Effective date: 19901008

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE FR IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRITISH TECHNOLOGY GROUP PLC

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRITISH TECHNOLOGY GROUP LTD

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR IT LI LU NL SE

REF Corresponds to:

Ref document number: 80035

Country of ref document: AT

Date of ref document: 19920915

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3874229

Country of ref document: DE

Date of ref document: 19921008

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19930610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930630

Ref country code: LI

Effective date: 19930630

Ref country code: CH

Effective date: 19930630

Ref country code: BE

Effective date: 19930630

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
BERE Be: lapsed

Owner name: BRITISH TECHNOLOGY GROUP LTD

Effective date: 19930630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19940101

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed

Ref document number: 88305317.5

Effective date: 19940110

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19950608

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19950830

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19970228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19970301

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050610